Mediar bags $105 mn from big pharmas to pursue fibrosis treatments
Mediar Therapeutics gets $105 million financing from Novartis, Pfizer, Eli Lilly and Bristol Myers to advance portfolio of first-in-class fibrosis therapies.
Medical
Pharma